iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 TherapyGlobeNewsWire · Oct 13, 2026
Squarepoint Ops LLC Makes New Investment in iBio, Inc. $IBIODefense World · Sep 19, 2026
iBio to Participate in the 2026 Wells Fargo Annual Healthcare ConferenceGlobeNewsWire · Sep 1, 2026
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · Aug 28, 2026
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical OfficerGlobeNewsWire · Aug 4, 2026iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 28, 2026 | -$0.07 | -$0.04 | Beat |
| May 12, 2026 | -$0.06 | -$0.07 | Miss |
| Feb 10, 2026 | -$0.08 | -$0.09 | Miss |
| Nov 12, 2025 | -$0.07 | -$0.11 | Miss |
| Sep 5, 2025 | -$0.39 | -$0.31 | Beat |
| May 2, 2025 | -$0.39 | -$0.49 | Miss |